title: [The preparation and study on hepatic targeting tendency of galactosyl-anti-CD3-McAb in mice].
abstract: OBJECTIVE
  This study sought to reduce the recurrence rate of primary liver cacer (PLC) after hepatectomy by increasing the concentration of infiltrating lymphocytes(TILs) at the target organ.
  
  
  METHODS
  It has been reported that galactosyl-anti-CD3-McAb has an obvious hepatic targeting tendency in vitro. On the basis of that work, the present authors conducted a study in mice. Galactosyl-anti-CD3-McAb was prepared and its carbohydrate density was measured with the phenol-sulphyric acid method, and then anti-CD3-McAb (labeled with 125I) and galactosyl-anti-CD3-McAb (labeled with 131I) were infused respectively via the peripheral vein and the radioactivity in each organ was measured.
  
  
  RESULTS
  The carbohydrate density of galactosyl-anti-CD3-McAb in this experiment was 58.12, which effectively guaranteed the specific binding between galactosyl-anti-CD3-McAb and hepatic binding protein(HBP). It was also noticed that anti-CD3-McAb tended to aggregate in the lungs while being infused via the peripheral vein, and that galactosyl-anti-CD3-McAb had an obvious hepatic targeting tendency in vivo and it stayed in liver for quite a long period.
  
  
  CONCLUSIONS
  Galactosyl-anti-CD3-McAb has an obvious hepatic targeting tendency in vivo while being infused through peripheral vein; this may be due to the specific binding between galactose and HBP.
authors.affiliation: Department of Surgery, First Affiliated Hospital, WCUMS, Chengdu 610041, China.
authors.forename: L
authors.initials: L
authors.lastname: Yuan
authors.forename: S
authors.initials: S
authors.lastname: He
authors.forename: C
authors.initials: C
authors.lastname: Guan
authors.forename: Q
authors.initials: Q
authors.lastname: Pang
mesh_terms: D000818:Animals; D017252:CD3 Complex / Q000276:immunology; D004338:Drug Combinations; D005260:Female; D005690:Galactose; D008099:Liver / Q000378:metabolism*; D016246:Lymphocytes, Tumor-Infiltrating; D008297:Male; D051379:Mice; D016853:Muromonab-CD3 / Q000096:biosynthesis* / Q000493:pharmacokinetics; D011817:Rabbits; D011897:Random Allocation; D014018:Tissue Distribution
chemical_list: D017252:CD3 Complex; D004338:Drug Combinations; D016853:Muromonab-CD3; D005690:Galactose